Literature DB >> 21815912

Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.

Junling Yang1, Minxia M He, Wei Niu, Steven A Wrighton, Li Li, Yang Liu, Chuan Li.   

Abstract

AIM: The most common causes of variability in drug response include differences in drug metabolism, especially when the hepatic cytochrome P450 (CYP) enzymes are involved. The current study was conducted to assess the differences in CYP activities in human liver microsomes (HLM) of Chinese or Caucasian origin.
METHODS: The metabolic capabilities of CYP enzymes in 30 Chinese liver microsomal samples were compared with those of 30 Caucasian samples utilizing enzyme kinetics. Phenacetin O-deethylation, coumarin 7-hydroxylation, bupropion hydroxylation, amodiaquine N-desethylation, diclofenac 4'-hydroxylation (S)-mephenytoin 4'-hydroxylation, dextromethorphan O-demethylation, chlorzoxazone 6-hydroxylation and midazolam 1'-hydroxylation/testosterone 6β-hydroxylation were used as probes for activities of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A, respectively. Mann-Whitney U test was used to assess the differences.
RESULTS: The samples of the two ethnic groups were not significantly different in cytochrome-b(5) concentrations but were significantly different in total CYP concentrations and NADPH-P450 reductase activity (P < 0.05). Significant ethnic differences in intrinsic clearance were observed for CYP1A2, CYP2C9, CYP2C19 and CYP2E1; the median values of the Chinese group were 54, 58, 26, and 35% of the corresponding values of the Caucasian group, respectively. These differences were associated with differences in Michaelis constant or maximum velocity. Despite negligible difference in intrinsic clearance, the Michaelis constant of CYP2B6 appeared to have a significant ethnic difference. No ethnic difference was observed for CYP2A6, CYP2C8, CYP2D6 and CYP3A.
CONCLUSIONS: These data extend our knowledge on the ethnic differences in CYP enzymes and will have implications for drug discovery and drug therapy for patients from different ethnic origins.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21815912      PMCID: PMC3269586          DOI: 10.1111/j.1365-2125.2011.04076.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  48 in total

Review 1.  Inheritance and drug response.

Authors:  Richard Weinshilboum
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

Review 2.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Authors:  Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

3.  Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19.

Authors:  Takako Shimizu; Hirohide Ochiai; Fredrik Asell; Hiroshi Shimizu; Ryuta Saitoh; Yoshimasa Hama; Jun Katada; Munehiro Hashimoto; Hitoshi Matsui; Katsuhiko Taki; Tsuguchika Kaminuma; Michiko Yamamoto; Yoshitaka Aida; Akira Ohashi; Naoki Ozawa
Journal:  Drug Metab Pharmacokinet       Date:  2003       Impact factor: 3.614

4.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Authors:  Roza Ghotbi; Magnus Christensen; Hyung-Keun Roh; Magnus Ingelman-Sundberg; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-17       Impact factor: 2.953

5.  Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase.

Authors:  F Peter Guengerich; Martha V Martin; Christal D Sohl; Qian Cheng
Journal:  Nat Protoc       Date:  2009-08-06       Impact factor: 13.491

Review 6.  CYP induction-mediated drug interactions: in vitro assessment and clinical implications.

Authors:  Jiunn H Lin
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

7.  Validated assays for human cytochrome P450 activities.

Authors:  Robert L Walsky; R Scott Obach
Journal:  Drug Metab Dispos       Date:  2004-06       Impact factor: 3.922

8.  CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine.

Authors:  J A Carrillo; J Benitez
Journal:  Br J Clin Pharmacol       Date:  1996-06       Impact factor: 4.335

Review 9.  PM frequencies of major CYPs in Asians and Caucasians.

Authors:  Takaharu Mizutani
Journal:  Drug Metab Rev       Date:  2003 May-Aug       Impact factor: 4.518

10.  'LC-electrolyte effects' improve the bioanalytical performance of liquid chromatography/tandem mass spectrometric assays in supporting pharmacokinetic study for drug discovery.

Authors:  Li Wang; Yan Sun; Feifei Du; Wei Niu; Tong Lu; Jingmin Kan; Fang Xu; Kaihong Yuan; Tao Qin; Changxiao Liu; Chuan Li
Journal:  Rapid Commun Mass Spectrom       Date:  2007       Impact factor: 2.419

View more
  13 in total

1.  Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.

Authors:  Sheng Feng; Yumi Cleary; Neil Parrott; Pei Hu; Cornelia Weber; Yongqing Wang; Ophelia Q P Yin; Jun Shi
Journal:  Eur J Clin Pharmacol       Date:  2015-03-24       Impact factor: 2.953

2.  Editors' pick 2012.

Authors:  Lionel D Lewis; Andrew Somogyi; Yoon K Loke; Albert Ferro; Adam F Cohen; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

3.  Pharmacokinetics of Roflumilast and Its Active Metabolite Roflumilast N-Oxide in Healthy Chinese Subjects After Single and Multiple Oral Doses.

Authors:  Qian Li; Yiya Wang; Lingye Liu; Pengcheng Ma; Li Ding
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

4.  Study on inter-ethnic human differences in bioactivation and detoxification of estragole using physiologically based kinetic modeling.

Authors:  Jia Ning; Jochem Louisse; Bert Spenkelink; Sebastiaan Wesseling; Ivonne M C M Rietjens
Journal:  Arch Toxicol       Date:  2017-03-29       Impact factor: 5.153

5.  Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.

Authors:  Zoe E Barter; Geoffrey T Tucker; Karen Rowland-Yeo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

6.  A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers.

Authors:  Feifan Xie; An Vermeulen; Pieter Colin; Zeneng Cheng
Journal:  Br J Clin Pharmacol       Date:  2019-03-21       Impact factor: 4.335

7.  Methylation and its role in the disposition of tanshinol, a cardiovascular carboxylic catechol from Salvia miltiorrhiza roots (Danshen).

Authors:  Dan-dan Tian; Wei-wei Jia; Xin-wei Liu; Dan-dan Wang; Jun-hua Liu; Jia-jia Dong; Li Li; Fei-fei Du; Fang Xu; Feng-qing Wang; Yan Sun; Yu-xing Huang; Mei-juan Li; Li-hong Hu; Yan Zhu; Xiu-mei Gao; Chuan Li; Jun-ling Yang
Journal:  Acta Pharmacol Sin       Date:  2015-04-20       Impact factor: 6.150

8.  Population Pharmacokinetic and Exposure-dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients.

Authors:  Valérie Cosson; Franziska Schaedeli-Stark; Mona Arab-Alameddine; Clarisse Chavanne; Elena Guerini; Michael Derks; Navita L Mallalieu
Journal:  Clin Transl Sci       Date:  2018-06-27       Impact factor: 4.689

9.  Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo.

Authors:  Haifeng Zhang; Na Gao; Xin Tian; Tingting Liu; Yan Fang; Jun Zhou; Qiang Wen; Binbin Xu; Bing Qi; Jie Gao; Hongmeng Li; Linjing Jia; Hailing Qiao
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

10.  Pharmacokinetic Study of Frovatriptan Succinate Tablet After Single and Multiple Oral Doses in Chinese Healthy Subjects.

Authors:  Hongquan Zheng; Yan Xia; Shengjun Qu; Lin Fan; Jingjing Zhang; Zhixiang Ma; Yangsheng Chen; Hongwei Fan
Journal:  Drug Des Devel Ther       Date:  2021-07-07       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.